HeartWare Drops Valtech Deal Under Shareholder Pressure; Stays Focused On VADs
This article was originally published in The Gray Sheet
Executive Summary
The ventricular-assist device company HeartWare International announced it was terminating its September 2015 agreement to buy heart-valve repair firm Valtech on the same day it disclosed an agreement with an activist shareholder group that opposed the deal.
You may also be interested in...
More Than Just A VAD Maker: HeartWare Broadens Heart Failure Focus With Valtech Buy
The deal will make HeartWare more of a go-to firm for heart-failure specialists, executives say. It comes soon after St. Jude Medical announced its acquisition of Thoratec, another VAD-focused firm whose technology will now be sold alongside a broader set of tools for heart-failure caregivers.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.